Eisai Inc.: Phase II Study Results Showed Eisai’s Lenvatinib (E7080) Demonstrated an Objective Response Rate of 59% in Radioiodine (RAI)-Refractory Differentiated Thyroid Cancer

Preliminary results of a Phase II single-arm study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai’s lenvatinib (USAN) demonstrated an Objective Response Rate (ORR) of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). These results will be presented during an ASCO oral session on June 6, 2011.